Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy

Frederick Wolfe, Kaleb Michaud

Research output: Contribution to journalArticle

296 Citations (Scopus)

Abstract

PURPOSE: We sought to determine the frequency of heart failure in patients with rheumatoid arthritis, and to determine its predictors, particularly the use of anti-tumor necrosis factor (TNF) therapy. METHODS: Rheumatoid arthritis (n = 13,171) and osteoarthritis (n = 2568) patients were studied during a 2-year period ending in June 2002. The diagnosis of heart failure was based on self-report or review of medical records. Propensity scores were used to adjust for the risk of anti-TNF (infliximab and etanercept) prescription. RESULTS: Heart failure was more common among patients with rheumatoid arthritis (3.9% [n = 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for differences in demographic characteristics. Patients with rheumatoid arthritis had similar risk factors for heart failure (e.g., hypertension, prior myocardial infarction, diabetes, advanced age) as persons in population-based studies. Heart failure was significantly (P <0.05) less common in anti-TNF-treated patients (3.1% [180/5832]) than in the remaining patients (3. 8% [281/7339]), even after adjusting for baseline differences. In the absence of pre-existing cardiovascular disease, the risk of heart failure was low (0.4% [24/6251]) and was not related to anti-TNF therapy. CONCLUSION: Our results suggest that rheumatoid arthritis increases the risk of heart failure, which may be ameliorated by anti-TNF therapies.

Original languageEnglish (US)
Pages (from-to)305-311
Number of pages7
JournalAmerican Journal of Medicine
Volume116
Issue number5
DOIs
StatePublished - Mar 1 2004

Fingerprint

Rheumatoid Arthritis
Heart Failure
Tumor Necrosis Factor-alpha
Osteoarthritis
Therapeutics
Propensity Score
Preexisting Condition Coverage
Self Report
Medical Records
Prescriptions
Cardiovascular Diseases
Myocardial Infarction
Demography
Hypertension
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Heart failure in rheumatoid arthritis : Rates, predictors, and the effect of anti-tumor necrosis factor therapy. / Wolfe, Frederick; Michaud, Kaleb.

In: American Journal of Medicine, Vol. 116, No. 5, 01.03.2004, p. 305-311.

Research output: Contribution to journalArticle

@article{a60d9b7160674ac0b6de7bb96ace28ac,
title = "Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy",
abstract = "PURPOSE: We sought to determine the frequency of heart failure in patients with rheumatoid arthritis, and to determine its predictors, particularly the use of anti-tumor necrosis factor (TNF) therapy. METHODS: Rheumatoid arthritis (n = 13,171) and osteoarthritis (n = 2568) patients were studied during a 2-year period ending in June 2002. The diagnosis of heart failure was based on self-report or review of medical records. Propensity scores were used to adjust for the risk of anti-TNF (infliximab and etanercept) prescription. RESULTS: Heart failure was more common among patients with rheumatoid arthritis (3.9{\%} [n = 461]) than in those with osteoarthritis (2.3{\%} [n = 87]), after adjusting for differences in demographic characteristics. Patients with rheumatoid arthritis had similar risk factors for heart failure (e.g., hypertension, prior myocardial infarction, diabetes, advanced age) as persons in population-based studies. Heart failure was significantly (P <0.05) less common in anti-TNF-treated patients (3.1{\%} [180/5832]) than in the remaining patients (3. 8{\%} [281/7339]), even after adjusting for baseline differences. In the absence of pre-existing cardiovascular disease, the risk of heart failure was low (0.4{\%} [24/6251]) and was not related to anti-TNF therapy. CONCLUSION: Our results suggest that rheumatoid arthritis increases the risk of heart failure, which may be ameliorated by anti-TNF therapies.",
author = "Frederick Wolfe and Kaleb Michaud",
year = "2004",
month = "3",
day = "1",
doi = "10.1016/j.amjmed.2003.09.039",
language = "English (US)",
volume = "116",
pages = "305--311",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Heart failure in rheumatoid arthritis

T2 - Rates, predictors, and the effect of anti-tumor necrosis factor therapy

AU - Wolfe, Frederick

AU - Michaud, Kaleb

PY - 2004/3/1

Y1 - 2004/3/1

N2 - PURPOSE: We sought to determine the frequency of heart failure in patients with rheumatoid arthritis, and to determine its predictors, particularly the use of anti-tumor necrosis factor (TNF) therapy. METHODS: Rheumatoid arthritis (n = 13,171) and osteoarthritis (n = 2568) patients were studied during a 2-year period ending in June 2002. The diagnosis of heart failure was based on self-report or review of medical records. Propensity scores were used to adjust for the risk of anti-TNF (infliximab and etanercept) prescription. RESULTS: Heart failure was more common among patients with rheumatoid arthritis (3.9% [n = 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for differences in demographic characteristics. Patients with rheumatoid arthritis had similar risk factors for heart failure (e.g., hypertension, prior myocardial infarction, diabetes, advanced age) as persons in population-based studies. Heart failure was significantly (P <0.05) less common in anti-TNF-treated patients (3.1% [180/5832]) than in the remaining patients (3. 8% [281/7339]), even after adjusting for baseline differences. In the absence of pre-existing cardiovascular disease, the risk of heart failure was low (0.4% [24/6251]) and was not related to anti-TNF therapy. CONCLUSION: Our results suggest that rheumatoid arthritis increases the risk of heart failure, which may be ameliorated by anti-TNF therapies.

AB - PURPOSE: We sought to determine the frequency of heart failure in patients with rheumatoid arthritis, and to determine its predictors, particularly the use of anti-tumor necrosis factor (TNF) therapy. METHODS: Rheumatoid arthritis (n = 13,171) and osteoarthritis (n = 2568) patients were studied during a 2-year period ending in June 2002. The diagnosis of heart failure was based on self-report or review of medical records. Propensity scores were used to adjust for the risk of anti-TNF (infliximab and etanercept) prescription. RESULTS: Heart failure was more common among patients with rheumatoid arthritis (3.9% [n = 461]) than in those with osteoarthritis (2.3% [n = 87]), after adjusting for differences in demographic characteristics. Patients with rheumatoid arthritis had similar risk factors for heart failure (e.g., hypertension, prior myocardial infarction, diabetes, advanced age) as persons in population-based studies. Heart failure was significantly (P <0.05) less common in anti-TNF-treated patients (3.1% [180/5832]) than in the remaining patients (3. 8% [281/7339]), even after adjusting for baseline differences. In the absence of pre-existing cardiovascular disease, the risk of heart failure was low (0.4% [24/6251]) and was not related to anti-TNF therapy. CONCLUSION: Our results suggest that rheumatoid arthritis increases the risk of heart failure, which may be ameliorated by anti-TNF therapies.

UR - http://www.scopus.com/inward/record.url?scp=1242315583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242315583&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2003.09.039

DO - 10.1016/j.amjmed.2003.09.039

M3 - Article

C2 - 14984815

AN - SCOPUS:1242315583

VL - 116

SP - 305

EP - 311

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 5

ER -